• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Nazca buys biopharmaceutical company Diater in €45m deal

  • Alessia Argentieri
  • Alessia Argentieri
  • 07 June 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Spanish mid-market GP Nazca Capital has acquired an 85% stake in biopharmaceutical company Diater from pharma specialist Ferrer.

The deal is valued at €45m, which equates to 9x the company's 2018 EBITDA.

Diater co-founders Ricardo Palacios and José Ángel López, chair and CEO of the company respectively, will reinvest in the business alongside other members of the management team.

Diater

  • DEAL:

    MBO

  • VALUE:

    €45m

  • LOCATION:

    Leganés

  • SECTOR:

    Biotechnology

  • FOUNDED:

    1999

  • TURNOVER:

    €17m (2018); €20m (2019)

  • EBITDA:

    €5m (2018)

  • STAFF:

    110

  • VENDOR:

    Ferrer Group

The GP intends to support Diater's growth by investing in R&D, developing new diagnosis products and immunotherapy treatments, and boosting its expansion into new market segments, both domestically and internationally. In addition, the company intends to pursue a buy-and-build strategy in order to consolidate and expand its market position and complement its product range with new acquisitions.

This is the fifth investment made by Nazca Fund IV, which closed on €275m in 2017 and is now around 60% deployed. The vehicle deploys equity tickets in the €15-50m bracket to acquire majority or significant minority stakes in Iberian companies operating in a wide range of sectors - primarily business services, retail, industrial, logistics and healthcare - with revenues ranging between €15-200m. 

In addition to the equity drawn down from the fund, CaixaBank provided a debt package to support the deal, Unquote understands.

Company
Founded in 1999 and headquartered in Leganés, near Madrid, Diater is a biopharmaceutical company specialising in allergy diagnostics and allergen immunotherapy. The company employs a staff of 110 people in two manufacturing plants located in Madrid. It treats 55,000 patients per year and exports 20% of its products outside Spain. Diater generated EBITDA of €5m from revenues of €17m in 2018 and expects to reach turnover of €20m in 2019.

People
Nazca Private Equity – Carlos Pérez de Jáuregui (partner).
Diater - Ricardo Palacios (co-founder, chair); José Ángel López (co-founder, CEO).

Advisers
Equity - WindCorp Translink (corporate finance); PwC (financial due diligence); Herbert Smith Freehills (legal).
Vendor - Deloitte (corporate finance).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Southern Europe
  • Healthcare
  • Spain
  • Deloitte
  • PwC

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013